Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory B-cell ALL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05054257
What this trial is testing

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
Institute of Hematology and Blood Transfusion, Czech Republic 10
Early research (Phase 1)Study completedNCT05950334
What this trial is testing

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Who this might be right for
Relapsed/Refractory B-Cell Lymphoma
Fate Therapeutics 20
Testing effectiveness (Phase 2)Study completedNCT01369849
What this trial is testing

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Study completedNCT04182204
What this trial is testing

Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 270
Testing effectiveness (Phase 2)Study completedNCT03456726
What this trial is testing

Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT07042438
What this trial is testing

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+3 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Early research (Phase 1)UnknownNCT04384393
What this trial is testing

Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

Who this might be right for
B Cell Malignancy
Fundamenta Therapeutics, Ltd. 30
Early research (Phase 1)Study completedNCT04067414
What this trial is testing

Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more
Institute of Hematology & Blood Diseases Hospital, China 12
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Early research (Phase 1)Not Yet RecruitingNCT07790575
What this trial is testing

Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
Cytopenia
Saurabh Dahiya 16
Testing effectiveness (Phase 2)Looking for participantsNCT06235229
What this trial is testing

GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd. 110
Very early researchLooking for participantsNCT07048353
What this trial is testing

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Who this might be right for
LymphomaB Cell LymphomaCD30+ Peripheral T-cell Lymphoma
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd 15
Testing effectiveness (Phase 2)Study completedNCT02077166
What this trial is testing

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC. 138
Testing effectiveness (Phase 2)Ended earlyNCT00112723
What this trial is testing

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+25 more
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT03277729
What this trial is testing

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+20 more
Fred Hutchinson Cancer Center 53
Testing effectiveness (Phase 2)UnknownNCT02060656
What this trial is testing

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust 92
Very early researchWithdrawnNCT05015972
What this trial is testing

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

Who this might be right for
B-cell Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Testing effectiveness (Phase 2)Looking for participantsNCT05092451
What this trial is testing

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Who this might be right for
B-Cell LymphomaMyelodysplastic Syndromes (MDS)Acute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT01589302
What this trial is testing

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Who this might be right for
Prolymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory/Relapsed Chronic Lymphocytic Leukemia
Kami Maddocks, MD 154
Next Page
56